Mode
Text Size
Log in / Sign up

Review of emulated trial finds levetiracetam continuation associated with lower 90-day mortality after strokeTaking This Common Stroke Medicine Might Save Lives After Discharge

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that continued levetiracetam after stroke was associated with lower 90-day mortality in an emulated trial of older Medicare beneficiaries.

This review synthesizes an emulated target trial using traditional Medicare claims data (2008-2021) to estimate the association between continued outpatient levetiracetam use and 90-day mortality after acute ischemic stroke. The analysis included 3,212 eligible Medicare beneficiaries aged ≥66 years, comparing those with a new levetiracetam dispensation within a 14-day grace period post-discharge to those without.

The authors report that continued levetiracetam was associated with lower 90-day mortality than discontinuation. The absolute risk difference was -9 per 1,000 (95% CI: -12 to -5), corresponding to 53 versus 62 deaths per 1,000. This observational, claims-based analysis cannot establish causation and may be subject to unmeasured confounding.

Safety outcomes, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. The authors note that findings are specific to older Medicare beneficiaries and may not generalize to other populations or care settings.

Practice relevance is restrained: results suggest potential benefits of continuing levetiracetam beyond the immediate post-stroke period, but should be interpreted as an association pending confirmatory randomized evidence.

Stroke is a major health problem for seniors across the country. Many older people take medicine to prevent seizures after the event. Doctors often worry about side effects and may stop these drugs too soon.

Post-stroke seizures can be frightening and dangerous for patients. However, the long-term impact of the medication itself is often debated.

The Surprising Shift In Care

For years, we believed stopping the medicine was safer. But here is the twist: keeping it on board might help you live longer. This new study challenges what we thought we knew about recovery.

Doctors used to think less medication was always better for older bodies. Now, we see that stability might be more important than simplicity.

How The Medicine Works Simply

Think of your brain like a house with a security system. After a stroke, that system can get glitchy and trigger false alarms. The medicine acts like a stabilizer to keep the electrical signals calm.

It helps prevent the brain from becoming overactive during healing. This stability might protect vital organs from stress caused by seizures.

Study Snapshot Details Explained

Researchers looked at over 3,200 older adults from Medicare records. They tracked who kept taking the drug for three months after leaving the hospital. The data covered a long time, from 2008 to 2021.

The average age of the patients was 76 years old. This group represents a large portion of the senior population in the United States.

People who continued the medication had fewer deaths in the first 90 days. There were 9 fewer deaths for every 1,000 people who kept taking the pill. This benefit was strongest for patients aged 75 and older.

While the number sounds small, it represents a significant number of lives saved. The risk difference was clear even after adjusting for other health issues.

This doesn’t mean this treatment is available yet.

Expert Perspective On Care

Experts say this adds a new piece to the puzzle of stroke care. It suggests the medicine does more than just stop seizures. It might protect the brain in other ways we do not fully understand.

The focus on the 75-and-older group is particularly interesting. It suggests age plays a key role in how the body responds to the drug.

Do not change your medicine without asking your doctor first. If you are older and had a stroke, discuss this new info with your care team. It is important to weigh the benefits against any side effects you feel.

Your doctor knows your full medical history better than anyone else. They can help you decide if the potential benefit is worth the risk.

Limitations To Keep In Mind

This study looked at records, not a controlled experiment. We cannot say for sure that the medicine caused the better survival. Other health factors might have played a role in the results.

It is important to remember that this is not a final answer. More rigorous testing is needed to prove cause and effect.

The Road Ahead For Research

Scientists need to run more tests to confirm these findings. Approval for new uses takes time and careful review. For now, this is a hopeful sign for older stroke survivors.

Future trials will help clarify exactly who benefits the most. Until then, this data offers a new perspective on recovery.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Objective: Levetiracetam is commonly prescribed for seizure prophylaxis after acute ischemic stroke (AIS) and often continued beyond discharge. While its short-term effectiveness for preventing post-stroke seizures is established, it is unclear whether prolonged use improves survival, particularly in older adults. We estimated the effect of continued levetiracetam use on 90-day mortality among Medicare beneficiaries after AIS. Methods: Using Traditional Medicare claims data (2008-2021), we identified beneficiaries aged [≥]66 years hospitalized for AIS who initiated outpatient levetiracetam within 90 days of discharge. After one month of continued post-stroke use of levetiracetam (start of follow-up), we compared 90-day mortality between patients with a new levetiracetam dispensation within a 14-day grace period post-follow up and those without one. We performed cloning, censoring and weighting to address immortal time bias and estimated standardized mortality risks, risk differences, and 95% confidence intervals (CI). Results: Among 3,212 eligible beneficiaries, 1,779 (55.4%) received a new levetiracetam dispensation within the 14-day grace period. Median age was 76 years (IQR 70-83); 57.8% were female. After adjustment for demographics, hospitalization characteristics, timing of initiation, and comorbidities, continued use was associated with lower 90-day mortality than discontinuation (53 vs 62 deaths per 1,000; risk difference -9 per 1,000; 95% CI: (-12,-5)). The reduction was observed primarily among patients aged [≥]75 years. Significance: Among older Medicare beneficiaries who initiated levetiracetam after AIS, continued outpatient use was associated with modestly lower 90-day mortality, particularly in those aged [≥]75 years. These findings suggest potential benefits of levetiracetam continuation beyond the immediate post-stroke period.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.